In cases where the classification is undefined but neddylation involvement is established, a follow-up study on EGFR neddylation revealed that vemurafenib, a BRAFV600E inhibitor used for colon cancers, has significantly improved efficacy when combined with pevonedistat (MLN4924) and cetuximab, an EGFR inhibitor47,52. This evidence concerns the gene EGFR and colonic neoplasm.